Steatotic Liver Disease in Newly Diagnosed and Gluten-Free Diet-Treated Adults with Celiac Disease
4 affiliations
- 1Faculty of Medicine, Internal Medicine and Gastroenterology Discipline, “Carol Davila” University of Medicine and Pharmacy, 020021 Bucharest, Romania
- 2Gastroenterology Department, “Dr. Carol Davila” Central Military University Emergency Hospital, 010825 Bucharest, Romania
- 3Medical Center for Diagnosis, Outpatient Treatment and Preventive Medicine, 011794 Bucharest, Romania
- 4National Institute for Mother and Child Health “Alessandrescu-Rusescu”, 020382 Bucharest, Romania
Abstract
Background and Aims: Celiac disease (CD) is increasingly recognized as a driver of metabolic alterations and liver dysfunction, also after initiation of the gluten-free diet (GFD). Our aim was to evaluate the metabolic profile and hepatic steatosis prevalence in patients with CD at diagnosis compared with those on long-term GFD. Methods: We conducted an observational cross-sectional study with an exploratory longitudinal analysis, including adult CD patients evaluated either at diagnosis (CD_new group) or during follow-up after at least 24 months of self-reported adherence to GFD (CD_GFD group); a non-CD patient group, who underwent the same diagnostic pathway but in whom CD was excluded, was used as control. Patients with diabetes and other chronic liver diseases were excluded. Clinical, metabolic, and hepatic parameters were assessed, including lipid profile, fasting glucose, and liver steatosis, determined by abdominal ultrasound and transient elastography with controlled attenuation parameter (CAP). Steatosis was defined as CAP ≥ 248 dB/m. Results: A total of 85 patients were included (27 CD_new, 40 CD_GFD, 18 non-CD controls). Patients in the CD_GFD group had higher body mass index compared with CD_new (24.5 vs. 21.9 kg/m2), while age and sex distribution were similar. Total cholesterol was numerically higher in CD_GFD (183.1 vs. 172.9 mg/dL), whereas triglycerides, HDL-C, and LDL-C were comparable between groups. Fasting glucose levels were similar and within the normoglycemic range. Hepatic steatosis was numerically more prevalent in CD_GFD, with ultrasound-defined steatosis observed in 37.5% compared to 25.9% in CD_new and 33.3% in non-CD controls without reaching statistical significance. CAP-defined steatosis was present in 32.5% of CD_GFD patients versus 18.5% in CD_new and 33.3% in non-CD controls, with numerically higher mean CAP values in the follow-up group (217 vs. 204 dB/m). In the exploratory longitudinal subset (n = 10), median CAP increased from 182.5 to 217.0 dB/m (p = 0.047). Sensitivity analysis using higher CAP thresholds showed that higher-grade steatosis was observed more frequently in GFD-treated patients. Liver stiffness measurements were similar between groups (4.3, 4.5, and 4.9 kPa, respectively). Conclusions: Long-term GFD-treated CD patients had higher BMI and numerically higher hepatic steatosis prevalence, although steatosis differences were not statistically significant and GFD-treated status was not independently associated with CAP-defined steatosis after adjustment. CD patients may present distinct metabolic profiles from diagnosis to long-term follow-up.
Related
- Additive interaction between ultrasound-diagnosed metabolic dysfunction-associated steatotic liver disease and hyperuricemia on impaired fasting glucose: a large-scale cross-sectional study
- Gluten-Free and Gluten-Restricted Diets in Multiple Sclerosis: A Systematic Review of Disease Activity and Patient-Reported Outcomes
- Beyond Self-Reported Adherence and Serology: Stool Gluten Immunogenic Peptides Detection to Assess Gluten Exposure in Children with Celiac Disease on a Gluten-Free Diet
- Symptom Profiles Compatible With Disorders of Gut‐Brain Interaction in Individuals With Coeliac Disease on a Long‐Term Gluten‐Free Diet
- A rare diagnosis during evaluation for metabolic dysfunction associated steatotic liver disease: Glycogen storage disease type Ia presenting during adolescence in a male with severe obesity
BibTeX
@article{balaban2026steatotic,
title = {{Steatotic Liver Disease in Newly Diagnosed and Gluten-Free Diet-Treated Adults with Celiac Disease}},
author = {Daniel Vasile Balaban and Laura Ioana Coman and Iulia Enache and Mihnea Cezar Gabriel Oprea Toma and Valentin Andrei Raduinea and Alexandru Marius Stancu and Sandica Nicoleta Bucurica and Raluca Simona Costache and Alina Popp and Mariana Jinga},
journal = {Nutrients},
year = {2026},
month = oct,
doi = {10.3390/nu18203419},
url = {https://www.mdpi.com/2072-6643/18/20/3419},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Steatotic Liver Disease in Newly Diagnosed and Gluten-Free Diet-Treated Adults with Celiac Disease
AU - Daniel Vasile Balaban
AU - Laura Ioana Coman
AU - Iulia Enache
AU - Mihnea Cezar Gabriel Oprea Toma
AU - Valentin Andrei Raduinea
AU - Alexandru Marius Stancu
AU - Sandica Nicoleta Bucurica
AU - Raluca Simona Costache
AU - Alina Popp
AU - Mariana Jinga
PY - 2026
DA - 2026/10/01
JO - Nutrients
DO - 10.3390/nu18203419
UR - https://www.mdpi.com/2072-6643/18/20/3419
AB - Background and Aims: Celiac disease (CD) is increasingly recognized as a driver of metabolic alterations and liver dysfunction, also after initiation of the gluten-free diet (GFD). Our aim was to evaluate the metabolic profile and hepatic steatosis prevalence in patients with CD at diagnosis compared with those on long-term GFD. Methods: We conducted an observational cross-sectional study with an exploratory longitudinal analysis, including adult CD patients evaluated either at diagnosis (CD_new group) or during follow-up after at least 24 months of self-reported adherence to GFD (CD_GFD group); a non-CD patient group, who underwent the same diagnostic pathway but in whom CD was excluded, was used as control. Patients with diabetes and other chronic liver diseases were excluded. Clinical, metabolic, and hepatic parameters were assessed, including lipid profile, fasting glucose, and liver steatosis, determined by abdominal ultrasound and transient elastography with controlled attenuation parameter (CAP). Steatosis was defined as CAP ≥ 248 dB/m. Results: A total of 85 patients were included (27 CD_new, 40 CD_GFD, 18 non-CD controls). Patients in the CD_GFD group had higher body mass index compared with CD_new (24.5 vs. 21.9 kg/m2), while age and sex distribution were similar. Total cholesterol was numerically higher in CD_GFD (183.1 vs. 172.9 mg/dL), whereas triglycerides, HDL-C, and LDL-C were comparable between groups. Fasting glucose levels were similar and within the normoglycemic range. Hepatic steatosis was numerically more prevalent in CD_GFD, with ultrasound-defined steatosis observed in 37.5% compared to 25.9% in CD_new and 33.3% in non-CD controls without reaching statistical significance. CAP-defined steatosis was present in 32.5% of CD_GFD patients versus 18.5% in CD_new and 33.3% in non-CD controls, with numerically higher mean CAP values in the follow-up group (217 vs. 204 dB/m). In the exploratory longitudinal subset (n = 10), median CAP increased from 182.5 to 217.0 dB/m (p = 0.047). Sensitivity analysis using higher CAP thresholds showed that higher-grade steatosis was observed more frequently in GFD-treated patients. Liver stiffness measurements were similar between groups (4.3, 4.5, and 4.9 kPa, respectively). Conclusions: Long-term GFD-treated CD patients had higher BMI and numerically higher hepatic steatosis prevalence, although steatosis differences were not statistically significant and GFD-treated status was not independently associated with CAP-defined steatosis after adjustment. CD patients may present distinct metabolic profiles from diagnosis to long-term follow-up.
SN - 2072-6643
ER -